甲、乙型肝炎口服二价DNA疫苗的研究
|
摘要
我国属于甲、乙型肝炎高发区,主要靠接种甲、乙型肝炎疫苗加以预防,由于现有的疫苗生产成本高,接种次数多等特点,使得这些疫苗难以推广应用,特别在贫困地区,需要研制一种安全、高效、方便和经济等优点的甲、乙型肝炎双价疫苗。目前,利用减毒沙门氏菌作为载体的多价DNA 口服疫苗,具有生产、免疫方便等优良特点。
本实验构建甲、乙型肝炎病毒的融合抗原基因SVPX,首先进行体外毕赤酵母细胞和CHO 细胞表达研究,结果表明,融合抗原基因在真核细胞里表达的蛋白具有甲、乙型肝炎抗原特性。构建含融合抗原基因的重组DNA 疫苗,以减毒沙门氏菌载体,进行小鼠口服免疫研究,结果表明,重组DNA 疫苗能够诱导机体产生针对两种抗原特异性体液和细胞免疫反应。同时,用IL-18 作为基因佐剂,能够进一步增强体液和细胞免疫的作用。本实验首次进行以减毒沙门氏菌为载体的甲、乙型肝炎口服二价DNA 疫苗的研究。
People in the world infected with HBV had a total of 20 hundred millions, and there were a total of 6.9 hundred million people in china. People with HBsAg had a total of 3.5 hundred millions, and one thirth of people with HBsAg were in china.In the world every year people’s deaths had 750 thousands after they infected HBV, and there were 280 thousand people in china. People in china infected with HAV had a total of 9.7 hundred millions, and infectious rate had exceeded 80%. HB and HA largely harmed to people. At present there had not special therapy to HB and HA which were mostly prevented by vaccine.Though HB vaccine, HA vaccine or combined vaccine of HB and HA were important to prevent HB and HA, there was much to be treated.For example, recombinant vaccine, attenuated vaccine, inactivated vaccine were producted, trafficed, deposited and selled in low temperature and it was expensive.The vaccines were not popularized in poor region. , and many diseases were infected by injecting syringe.It was very important to develop a new double valence DNA vaccine of HBV and HAV, which was easily immunized, low charge, and good immune effect.
DNA vaccine was immunized by many methods. Attenuated Salmonella typhimurium with DNA vaccine was easily immunized and economical. At the same time genetic background of Salmonella was clearly known and easily done by people. Because antibiotics in vaccine was not permitted by FDA of America, prokaryotic expression vector asd-balanced lethal system was constructed by Nakayama, which had no antibiotics. In our study, fusion gene of HBV and HAV antigen which was not
expressed in prokaryotic expression vector was expressed in eukaryotic expression vector asd-pVAX1, which was constructed in the study and was complementary to E.coli X6212, Salmonella typhimuriumX3730 and Salmonella typhimuriumX4550.
Hybrid gene SVPX was constructed by overlapping PCR with template of S gene of HBsAg and VPX gene of HAV complex multiepitope , and was then expressed in Pichia yeast and CHO host cells. Recombinant vectors asd-pVAX1-SVPX and pVAX1-SVPX were respectively transformed into Salmonella typhimurium X4550. Recombinant Salmonella typhimuriumX4550 with asd-pVAX1-SVPX and pVAX1-SVPX were immunized to mouse, then specific humoral and cellular immunity were detected. Hybrid gene SVPX whose DNA fragement was about 0.8kb, was constructed by overlapping PCR with template of S gene of HBsAg and VPX gene of HAV complex multiepitope. Specific primer was planned by us. Considering the special structure of two conformational epitopes, we inserted several flexible amino acids into two epitopes. A specific DNA fragment about 0.8kb was recovered. Ligation of the DNA with the vector pMD18-T was done and then transformed into competent host strain Escherichia coli JM109. Plasmids were isolated from recombinant clones by alkaline lysis, and PCR identification, restriction analysis and DNA sequencing were carried out to verify the recombinant plasmids pMD-SVPX. All results showed that the SVPX DNA was the exact fragment.
According to Pichia yeast expression vector pPICZαC MCS and SVPX sequence, we planned two specific primers, and EcoR I & Kpn I were respectively belonged to upstream and downstream primer. A specific DNA fragment about 0.8kb was recovered. Ligation of the DNA with the vector pMD18-T was done and then transformed into competent host strain Escherichia coli JM109. Positive recombinant plasmid was sequenced ,and results showed that hybrid gene SVPX sequence was exact. The fusion gene SVPX DNA, cut from the recombinant pMD-SVPX with EcoR I & Kpn I, was
inserted into the yeast expression vector pPICZαC by the same digestion. The recombinant yeast expression plasmid was named as pPICZαC-SVPX. The recombinants were then transformed into competent Pichia yeast host cells GS115 by electroporation. The positive clones were screened by ZeocinTM resistance, and their genomic DNA were isolated and then amplified by PCR, using vector primers 5′AOX1 paired with 3′AOX1, and specific primers pP1 paired with pP2, to determine the integration of the interest gene into the Pichia genome. Most clones with ZeocinTM resistance were confirmed to be positive Pichia integrants by PCR amplification. When the recombinant Pichia strain was induced by adding of methaol to a final concentration of 0.5%, mRNA transcripted from the interest gene was detected by RT-PCR amplification, and the band of interest protein was found in the condensed supernatant by SDS-PAGE and Western blot.
According to eukaryotic expression vector asd-pVAX1 and pVAX1 MCS and SVPX sequence, Specific primers were planned by us, and EcoR and Xho I were respectively belonged to upstream and downstream primer. In order to enhance the expression yields of the fusion antigen, a Kozak sequence was introduced into the designed fusion gene.A specific DNA fragment about 0.8kb was recovered.Ligation of the DNA with the vector pMD18-T was done and then transformed into competent host strain Escherichia coli JM109. Positive recombinant plasmid was sequenced ,and results showed that hybrid gene SVPX sequence was exact.The fusion gene SVPX DNA, cut from the recombinant pMD-SVPX with EcoR I & Xho I, was inserted into the eukaryotic expression vector asd-pVAX1 and pVAX1 by the same digestion. The recombinant eukaryotic expression plasmids were named as asd-pVAX1-SVPX and pVAX1-SVPX.
CHO cells were transfected with recombinant plasmid asd-pVAX1-SPVX and pVAX1-SVPX by means of liposome respectively,and the fursion gene was
instantaneously expressed. By RT-PCR amplification, ELISA assay and Western Blot, the fusion gene SVPX was expressed in transfected CHO cells successfully.
Recombinant plasmids of asd-pVAX1-SPVX and pVAX1-SVPX were transformed into competent attenuated Salmonella typhimurium X3730 and X4550 in turn by electroporation. Recombinant attenuated Salmonella typhimurium X4550(asd-pVAX1-SPVX)and X4550(pVAX1-SPVX)were constructed and tested, and the results showed that the X4550(asd-pVAX1-SPVX)and X4550(pVAX1-SPVX)were stable, and could normally grow. Recombinant X4550(asd-pVAX1-SPVX)and X4550(pVAX1-SPVX)below 1×1010 cfu were safe when orally administered into BALB/c mouse. After recombinant X4550 ( asd-pVAX1-SPVX ) and X4550(pVAX1-SPVX)of 109cfu which is a safe dose were respectively orally administered into BALB/c mice for 3 times, the level of serum sepecific antibodies, cytotoxicity activity of specific CTL, the numbers of spleen T lymphocytes subgroups, and cytokine level of Th1 were examined.The results showed that the DNA vaccine could increase the percentage of the T cell subgroups , elicit serum specific antibody and specific cytotoxicity activity of CTL to HBsAg and HAAg. The immunized mice could product Th1 cytokine.
Recombinant X4550(asd-pVAX1-IL-18) and X4550( pVAX1-IL-18) were constructed in our sudy. Combined group of X4550(asd-pVAX1-SPVX)& X4550(asd-pVAX1-IL-18), and X4550(asd-pVAX1-SPVX)& X4550(asd-pVAX1-IL-18)were orally adiminstered into BALB/c mice. At the same time there were control groups of X4550(asd-pVAX1-SPVX)and X4550(pVAX1-SPVX)with 109 cfu of Each recombinant X4550 was orally administered into BALB/c mice for 3 times.The level of serum sepecific antibodies, cytotoxicity activity of specific CTL, the numbers of spleen T lymphocytes subgroups, and cytokine level of Th1 were examined.The results showed that the percentage of the T cell subgroups , level of sera specific
本实验构建甲、乙型肝炎病毒的融合抗原基因SVPX,首先进行体外毕赤酵母细胞和CHO 细胞表达研究,结果表明,融合抗原基因在真核细胞里表达的蛋白具有甲、乙型肝炎抗原特性。构建含融合抗原基因的重组DNA 疫苗,以减毒沙门氏菌载体,进行小鼠口服免疫研究,结果表明,重组DNA 疫苗能够诱导机体产生针对两种抗原特异性体液和细胞免疫反应。同时,用IL-18 作为基因佐剂,能够进一步增强体液和细胞免疫的作用。本实验首次进行以减毒沙门氏菌为载体的甲、乙型肝炎口服二价DNA 疫苗的研究。
People in the world infected with HBV had a total of 20 hundred millions, and there were a total of 6.9 hundred million people in china. People with HBsAg had a total of 3.5 hundred millions, and one thirth of people with HBsAg were in china.In the world every year people’s deaths had 750 thousands after they infected HBV, and there were 280 thousand people in china. People in china infected with HAV had a total of 9.7 hundred millions, and infectious rate had exceeded 80%. HB and HA largely harmed to people. At present there had not special therapy to HB and HA which were mostly prevented by vaccine.Though HB vaccine, HA vaccine or combined vaccine of HB and HA were important to prevent HB and HA, there was much to be treated.For example, recombinant vaccine, attenuated vaccine, inactivated vaccine were producted, trafficed, deposited and selled in low temperature and it was expensive.The vaccines were not popularized in poor region. , and many diseases were infected by injecting syringe.It was very important to develop a new double valence DNA vaccine of HBV and HAV, which was easily immunized, low charge, and good immune effect.
DNA vaccine was immunized by many methods. Attenuated Salmonella typhimurium with DNA vaccine was easily immunized and economical. At the same time genetic background of Salmonella was clearly known and easily done by people. Because antibiotics in vaccine was not permitted by FDA of America, prokaryotic expression vector asd-balanced lethal system was constructed by Nakayama, which had no antibiotics. In our study, fusion gene of HBV and HAV antigen which was not
expressed in prokaryotic expression vector was expressed in eukaryotic expression vector asd-pVAX1, which was constructed in the study and was complementary to E.coli X6212, Salmonella typhimuriumX3730 and Salmonella typhimuriumX4550.
Hybrid gene SVPX was constructed by overlapping PCR with template of S gene of HBsAg and VPX gene of HAV complex multiepitope , and was then expressed in Pichia yeast and CHO host cells. Recombinant vectors asd-pVAX1-SVPX and pVAX1-SVPX were respectively transformed into Salmonella typhimurium X4550. Recombinant Salmonella typhimuriumX4550 with asd-pVAX1-SVPX and pVAX1-SVPX were immunized to mouse, then specific humoral and cellular immunity were detected. Hybrid gene SVPX whose DNA fragement was about 0.8kb, was constructed by overlapping PCR with template of S gene of HBsAg and VPX gene of HAV complex multiepitope. Specific primer was planned by us. Considering the special structure of two conformational epitopes, we inserted several flexible amino acids into two epitopes. A specific DNA fragment about 0.8kb was recovered. Ligation of the DNA with the vector pMD18-T was done and then transformed into competent host strain Escherichia coli JM109. Plasmids were isolated from recombinant clones by alkaline lysis, and PCR identification, restriction analysis and DNA sequencing were carried out to verify the recombinant plasmids pMD-SVPX. All results showed that the SVPX DNA was the exact fragment.
According to Pichia yeast expression vector pPICZαC MCS and SVPX sequence, we planned two specific primers, and EcoR I & Kpn I were respectively belonged to upstream and downstream primer. A specific DNA fragment about 0.8kb was recovered. Ligation of the DNA with the vector pMD18-T was done and then transformed into competent host strain Escherichia coli JM109. Positive recombinant plasmid was sequenced ,and results showed that hybrid gene SVPX sequence was exact. The fusion gene SVPX DNA, cut from the recombinant pMD-SVPX with EcoR I & Kpn I, was
inserted into the yeast expression vector pPICZαC by the same digestion. The recombinant yeast expression plasmid was named as pPICZαC-SVPX. The recombinants were then transformed into competent Pichia yeast host cells GS115 by electroporation. The positive clones were screened by ZeocinTM resistance, and their genomic DNA were isolated and then amplified by PCR, using vector primers 5′AOX1 paired with 3′AOX1, and specific primers pP1 paired with pP2, to determine the integration of the interest gene into the Pichia genome. Most clones with ZeocinTM resistance were confirmed to be positive Pichia integrants by PCR amplification. When the recombinant Pichia strain was induced by adding of methaol to a final concentration of 0.5%, mRNA transcripted from the interest gene was detected by RT-PCR amplification, and the band of interest protein was found in the condensed supernatant by SDS-PAGE and Western blot.
According to eukaryotic expression vector asd-pVAX1 and pVAX1 MCS and SVPX sequence, Specific primers were planned by us, and EcoR and Xho I were respectively belonged to upstream and downstream primer. In order to enhance the expression yields of the fusion antigen, a Kozak sequence was introduced into the designed fusion gene.A specific DNA fragment about 0.8kb was recovered.Ligation of the DNA with the vector pMD18-T was done and then transformed into competent host strain Escherichia coli JM109. Positive recombinant plasmid was sequenced ,and results showed that hybrid gene SVPX sequence was exact.The fusion gene SVPX DNA, cut from the recombinant pMD-SVPX with EcoR I & Xho I, was inserted into the eukaryotic expression vector asd-pVAX1 and pVAX1 by the same digestion. The recombinant eukaryotic expression plasmids were named as asd-pVAX1-SVPX and pVAX1-SVPX.
CHO cells were transfected with recombinant plasmid asd-pVAX1-SPVX and pVAX1-SVPX by means of liposome respectively,and the fursion gene was
instantaneously expressed. By RT-PCR amplification, ELISA assay and Western Blot, the fusion gene SVPX was expressed in transfected CHO cells successfully.
Recombinant plasmids of asd-pVAX1-SPVX and pVAX1-SVPX were transformed into competent attenuated Salmonella typhimurium X3730 and X4550 in turn by electroporation. Recombinant attenuated Salmonella typhimurium X4550(asd-pVAX1-SPVX)and X4550(pVAX1-SPVX)were constructed and tested, and the results showed that the X4550(asd-pVAX1-SPVX)and X4550(pVAX1-SPVX)were stable, and could normally grow. Recombinant X4550(asd-pVAX1-SPVX)and X4550(pVAX1-SPVX)below 1×1010 cfu were safe when orally administered into BALB/c mouse. After recombinant X4550 ( asd-pVAX1-SPVX ) and X4550(pVAX1-SPVX)of 109cfu which is a safe dose were respectively orally administered into BALB/c mice for 3 times, the level of serum sepecific antibodies, cytotoxicity activity of specific CTL, the numbers of spleen T lymphocytes subgroups, and cytokine level of Th1 were examined.The results showed that the DNA vaccine could increase the percentage of the T cell subgroups , elicit serum specific antibody and specific cytotoxicity activity of CTL to HBsAg and HAAg. The immunized mice could product Th1 cytokine.
Recombinant X4550(asd-pVAX1-IL-18) and X4550( pVAX1-IL-18) were constructed in our sudy. Combined group of X4550(asd-pVAX1-SPVX)& X4550(asd-pVAX1-IL-18), and X4550(asd-pVAX1-SPVX)& X4550(asd-pVAX1-IL-18)were orally adiminstered into BALB/c mice. At the same time there were control groups of X4550(asd-pVAX1-SPVX)and X4550(pVAX1-SPVX)with 109 cfu of Each recombinant X4550 was orally administered into BALB/c mice for 3 times.The level of serum sepecific antibodies, cytotoxicity activity of specific CTL, the numbers of spleen T lymphocytes subgroups, and cytokine level of Th1 were examined.The results showed that the percentage of the T cell subgroups , level of sera specific
引文
[1] 戴志澄,祁国明。中国病毒性肝炎血清流行病学调查(上卷)。北京科学技术文献出版社,1997,21~28。
[2] Emini EA, Hughes JV, Perlow DS, et al. Induction of hepatitis A virus-neutralizing antibody by a virus-specific synthetic peptide. J Virol, 1985, 55(3): 836~839.
[3] Wheeler CM, Robertson BH, Van Nest G, et al. Structure of the hepatitis A virion: peptide mapping of the capsid region. J Virol, 1986, 58(2):307~313.
[4] Bosch A, Gonzalez-Dankaart JF, Haro I, et al. A new continuous epitope of hepatitis A virus. J Med Virol, 1998, 54(2): 95~102.
[5] Haro I, Perez S, Garcia M, Chan WC, et al.Liposome entrapment and immunogenic studies of a synthetic lipophilic multiple antigenic peptide bearing VP1 and VP3 domains of the hepatitis A virus: a robust method for vaccine design. FEBS Letters, 2003, 540: 133 ~140.
[6] Sun Z, Ming L, Zhu X, et al. Prevention and control of hepatitis B in China. J Med Virol, 2002, 67(3): 447~450.
[7] Zuckerman JN,Zuckerman AJ. Current topics in hepatitis B. J Infect, 2000, 41(2):130~136.
[8] Mackay P, Pasek M, Magazin M, et al. Production of immunologically active surface antigens of hepatitis B virus by Escherichia coli. Proc Natl Acad Sci USA, 1981,78(7): 4510~4514.
[9] Fujisawa Y, Ito Y, Sasada R, et al . Direct expression of hepatitis B surface antigen gene in E. coli. Nucleic Acids Res,1983, 11(11): 3581~3591.
[10] Tiollais P, Christine P, Dejean A. The hepatitis B virus. Nature, 1985, 371(6037): 489~495.
[11] Smith KM, Eaton AD, Finlayson LM, et al . Oral tolerance. Am J Respir Crit Care Med, 2000, 162(4 Pt 2): S175~178.
[12] Ogra PL, Faden H, Welliver RC. Vaccination strategies for mucosal immune responses. Clin Microbiol Rev, 2001, 14 : 430~445.
[13] Davis HL, McCluskie MJ, Gerin JL, et al. DNA vaccine for hepatitis B: evidence for immunogenicity in chimpanzees and comparison with other vaccines . Proc Natl Acad Sci USA, 1996, 93(14):7213~7218
[14] 冯子健,封秀红,叶莹,等。不同剂量国产重组酵母乙肝疫苗对成人免疫效果观察。中国公共卫生,2002,18 (2):215~216。
[15] Flehmig B, Heinricy U, Pfisterer M. Simultaneous vaccination for hepatitis A and B.J Infect Dis. 1990,161(5): 865~868.
[16] Papaevangelou G. Current combined vaccines with hepatitis B. Vaccine, 1998, 16 (Suppl ) : S69-72.
[17] Thoelen S, Van Damme P, Leentvaar-Kuypers A, et al. The first combined vaccine against hepatitis A and B: an overview. Vaccine, 1999, 17 (13~14): 1657~1662.
[18] Burgess MA,Rodger AJ,Waite SA,et al. Comparative immunogenicity and safety of two dosing schedules of a combined hepatitis A and B vaccine in healthy adolescent volunters: an open, randomised study. Vaccine, 2001,19:4835~4841.
[19] Kallinowski B, Bock HL, Clemens R, et al. Immunogenicity and reactogenicity of a combined hepatitis A/B candidate vaccine :first results. Liver, 1996, 16(4) :271~273.
[20] Leroux-Roels G, Moreau W, Desombere I, et al. Safety and immunogenicity of a combined hepatitis A and hepatitis B vaccine in young healthy adults. Scand J Gastrogenterol, 1996,31 (10) : 1027~1031.
[21] Nakayama K, Kelly SM, Curtiss R Ⅲ. Construction of an asd+ expression-cloning vector: stable maintenance and high level expression of cloned
genes in a Salmonella vaccine strain. Bio/Technology, 1988, 6: 693~697.
[22] Tacket CO, Kelly SM, Schodel F, et al. Safety and immunogenicity in humans of an attenuated salmonella typhi vaccine vector strain expressing plasmid-encoded hepatitis B antigens stabilized by the Asd-balanced lethal vector system. Infect Immun, 1997, 65(9):3381~3385
[23] Germanier R, Fuer E. Isolation and characterization of Gal E mutant Ty 21a of Salmonella typhi: a candidate strain for a live, oral typhoid vaccine. J Infect Dis. 1975, 131(5): 553~558.
[24] Stocker BA,Auxotrophic Salmonella typhi as live vaccine.Vaccine.1988, 6(2): 141~145.
[25] Hone D, Morona R, Attridge S, et al. Construction of defined galE mutants of Salmonella for use as vaccines. J Infect Dis, 1987, 156(1): 167~174.
[26] Curtiss R 3 rd, Kelly SM. Salmonella typhimurium deletion mutants lacking adenylate cyclase and cyclic AMP receptor protein are avirulent and immunogenic.Infect Immun. 1987, 55(12): 3035~3043.
[27] McFarland WC, Stocker BA. Effect of different purine auxotrophic mutations on mouse-virulence of a Vi-positive strain of Salmonella dublin and of two strains of Salmonella typhimurium. Microb Pathog, 1987, 3(2):129~141.
[28] Hohmann EL, Oletta CA, Miller SI. Evaluation of a phoP/phoQ-deleted, aroA-deleted live oral Salmonella typhi vaccine strain in human volunteers.Vaccine, 1996,14(1):19~24.
[29] Edwards MF,Stocker BA. Construction of delta aroA his delta pur strains of Salmonella typhi.J Bacteriol, 1988, 170(9): 3991~3995.
[30] O'callachan D, Maskell D, Liew FY, et al. Characterization of aromatic-and purine-dependent Salmonella typhimurium: attenuation, persistence and ability to induce protective immunity in BALB/c mice.Infect Immun , 1988 ,56 (2):419~423.
[31] Galan JE, Nakayama K, Curtiss R 3rd, et al. Cloning and characterization of the asd gene of Salmonella typhimurium: use in stable maintenance of recombinant plasmids in Salmonella vaccine strains.Gene, 1990, 94(1): 29~35
[32] Lowe DC, Savidge TC, Pickard D, et al. Characterization of candidate live oral Salmonella typhi vaccine strains harboring defined mutations in aroA, aroC and htrA. Infect Immun, 1999, 67(2): 700~707.
[33] Heithoff DM, Sinsheimer RL, Low DA, et al. An essential role for DNA adenine methylation in bacterial virulence.Science, 1999, 284(5416): 967~970.
[34] Curtiss R 3rd, Hassan J. Nonrecombinant and recombinant avirulent Salmonella vaccines for poultry. Vet immunol and Immunopathol, 1996, 54(1~4), 365~372.
[35] Ahmer BM, van Reeuwijk J, Watson PR, et al. Salmonella SirA is a global regulator of genes mediating enteroathogenesis. Mol.Microbiol, 1999, 31(3):971~982.
[36] Clements JD, E1-Morshidy S . Construction of a potential live oral bivalent vaccine for typhoid fever and cholera-Escherichia coli-related diarrheas. Infect Immun, 1984, 46(2):564~569.
[37] Giron JA, Xu JG, Gonzalez CR, et al. Simultaneous expression of CFA/I and CS3 colonization factor antigens of enterotoxigenic Escherichia coli by delta aroC, delta aroD Salmonella typhi vaccine strain CVD 908.Vaccine, 1995, 13(10):939~946.
[38] Valentine PJ, Devore BP, Heffron F. Identification of three highly mice than a prototypical aroA mutant. Infection and Immunity, 1998, 66(7): 3378~3383.
[39] Miller SI,Mekalanos JJ, Pulkkinen WS. Salmonella vaccines with mutations in the phoP virulence regulon. Res.Microbiol, 1990, 141(7~8): 817~821.
[40] Levine MM, Ferreccio C, Black RE, et al. Large-scale field trial of Ty21a live oral typhoid vaccine in enteric-coated capsule formulation. Lancet, 1987, 1(8541): 1049~1052.
[41] Chatfield SN ,Charles IG, Makoff AJ, et al . Use of the nirB promoter to direct the stable expression of heterologous antigens in Salmonella oral vaccine strains: development of a single-dose oral tetanus vaccine. Biotechnology, 1992, 10 (8): 888~ 892.
[42] Everest P, Frankel G, Li J, Lund P, et al. Expression of lacZ from the htrA, nirB and groE promoters in a Salmonella vaccine strain: influence of growth in mammalian cells. FEMS Microbiol Lett, 1995, 126(1):97~101.
[43] Huang Y, Hajishengallis G, Michalek SM. Construction and characterization of a Salmonella enterica serovar typhimurium clone expressing a salivary adhesin of Streptococcus mutants under control of the anaerobically inducible promoter. Infect Immun , 2000 , 68(3) :1549~1556.
[44] Oxer MD, Benthey CM, Doyle JG, et al . High level heterologous expression in E. coli using the anaerobically activated nirB promoter. Nucl Acids Res, 1991, 19(11) :2889~2992.
[45] Pasetti MF, Anderson RJ, Noriega FR, et al. Attenuated deltaguaBA Salmonella typhi vaccine strain CVD 915 as a live vector utilizing prokaryotic or eukaryotic expression systems to deliver foreign antigens and elicit immune responses. Clin Immunol, 1999, 92 (1): 76~89.
[46] Hone D, Attridge S, van den Bosch L, et al. A chromosomal integration system for stabilization of heterologous genes in Salmonella based vaccine strains.Microb Pathog, 1988, 5(6): 407~418.
[47] Strugnell RA, Maskell D, Fairweather N, et al. Stable expression of foreign antigens from the chromosome of Salmonella typhimurium vaccine strains.Gene, 1990, 88(1):57~63.
[48] Flynn JL, Weiss WR, Norris KA. Generation of a cytotoxic T-lymphocyte response using a Salmonella antigen-delivery system. Mol Microbiol, 1990, 4(12):
2111~2118.
[49] Morona R, Morona JK, Considine A, et al. Construction of K88-and K99-expressing clones of Salmonella typhimurium G30: immunogenicity following oral administration to pigs.Vaccine, 1994 , 12(6):513~517
[50] Redman TK, Harmon CC, Michalek SM.Oral immunization with recombinant Salmonella typhimurium expressing surface protein antigen A (SpaA) of Streptococcus sobrinus: effects of the Salmonella virulence plasmid on the induction of protective and sustained humoral responses in rats. Vaccine, 1996, 14(9): 868~878.
[51] Woo PC, Wong LP, Zheng BJ, et al. Unique immunogenicity of hepatitis B virus DNA vaccine presented by live-attenuated Salmonella typhimurium. Vaccine, 2001, 19 (20-22): 2945~2954.
[52] 陈东立,马清钧。表达霍乱CT-B 和LPS-O 抗原的鼠菌苗株的构建.生物工程学报,1997,13(l):47~52。
[53] Dunstan SJ, Simmons CP, Strugnell RA.Comparison of the abilities of different attenuated Salmonella typhimurium strains to elicit humoral immune responses against a heterologous antigen. Infect Immun, 1998, 66(2): 732~740.
[54] Fastad IN, Halstense TS, fausa O, et al. Heterogeneity of M-cell-associated B and T cells in human Peyers patches. Immunology, 1994, 83(3) :457~464.
[55] Clark MA, Jepson MA, Simmons NL, et al. Selective binding and transcytosis of Ulex europaeus 1 lectin by mouse Peyer's patch M-cells in vivo.Cell Tissue Res, 1995, 282(3):455~461.
[56] Jones BD, Ghori N, Faikow S.Salmonella typhimurium initiates murine infectin by penetrating and destroying the specialized epithelial M cells of the Peyer's patches. J ExP Med, 1994, 180(1):15~23
[57] Jensen VB,Harty JT, Jones BD. Interactions of the Invasive pathogens Salmonella typhimurium,Listeria monocytogenes, and Shigella flexneri with M Cells
and Murine Peyer’s Patches. Infect and Immun, 1998, 66(8) 3758~3766 .
[58] Hopkins SA, Niedergang F,Corhesy-Theulaz IE, et al. A recombinant Salinonella typhimurium vaccine strain is taken up and survives within murine Peyer’s Patch dendritic cells. Cell Microbiol, 2000, 2(1):59~68.
[59] Rescigno M.In Dendritic Cell:Biology and clinical application (ed.Thomson, MLa A.) 403~419 (Academic Press, San Diego, CA.1999)
[60] Hofer S, Rescigno M, Granucci F, et al . Differential activation of NF-kappa B subunits in dendritic cells in response to Gram-negative bacteria and to lipopolysaccharide. Microbes Infect, 2001, 3 (4) : 259~265.
[61] Giannasca PJ, Neutral MR. Interactions of microorganisms with intestinal M cells: mucosal invasion and induction of secretory immunity.Infect Agents Dis, 1993, 2(4): 242~248.
[62] Yrlid U, Wick MJ.Salmonella-induced apotosis of infected macrophages results in presentation of a bacteria-encoded antigen after uptake by bystander dendritic cells.J ExP Med, 2000, 191(4): 613~624.
[63] Figueroa-Bossi N, Uzzau S, Maloriol D, et al.Variable assortment of prophages provides a transferable repertoire of pathogenic determinants in Salmonella. Mol Microbiol. 2001, 39 (2): 260~271.
[64] Sznol M, Lin SL, Bermudes D, et al. Use of preferentially replicating bacterial for the treatment of cancer. J Clin invest, 2000, 105(8):1027~1030.
[65] Gentschev I, Dietrich G, Spreng S, et al. Use of the alpha-hemolysin secretion system of Escherichia coli for antigen delivery in the Salmonella typhi Ty21a vaccine strain. Int J Med Microbiol. 2004, 294(6):363~371.
[66] Stabel TJ, Mayfield JE, Tabatabai LB. Oral immunization of mice with attenuated Salmonella typhimurium containing a recombinant plasmid which codes for production of a 31-kilodalton protein of Brucella abortus.Infect Immun. 1990, 58(7):
2048~2055.
[67] Roland K, Karaca K, Sizemore D. Expression of Escherichia coli antigens in Salmonella typhimurium as a vaccine to prevent airsacculitis in chickens. Avian Dis. 2004,48(3):595~605.
[68] Baud D, Ponci F, Bobst M, Improved efficiency of a Salmonella-based vaccine against human papillomavirus type 16 virus-like particles achieved by using a codon-optimized version of L1. J Virol, 2004, 78(23):12901-12909.
[69] Woo PC, Wong LP, Zheng BJ, Yuen KY. Unique immunogenicity of hepatitis B virus DNA vaccine presented by live-attenuated Salmonella typhimurium.Vaccine,2001,19(20~22), 2945~2954.
[70] Karpenko LI, Nekrasova NA, Ilyichev AA,Comparative analysis using a mouse model of the immunogenicity of artificial VLP and attenuated Salmonella strain carrying a DNA-vaccine encoding HIV-1 polyepitope CTL-immunogen. Vaccine. 2004, 22 (13-14): 1692~1699.
[71] Pogonka T, Klotz C, Kovacs F, et al. A single dose of recombinant Salmonella typhimurium induces specific humoral immune responses against heterologous Eimeria tenella antigens in chicken. Int J Parasitol. 2003, 33(1):81-88.
[72] Stager S, Gottstein B, Muller N. Systemic and local antibody response in mice induced by a recombinant peptide fragment from Giardia lamblia variant surface protein (VSP) H7 produced by a Salmonella typhimurium vaccine strain. Int J Parasitol. 1997, 27(8): 965~971
[73] Sadoff JC, Ballou WR, Baron LS, et al. Oral Saimonella typhimurium vaccine expressing circumsporozoite protein protects against malaria.Science, 1988, 240(4850): 336~338
[74] Yuhua L, Kunyuan G, Hui C, et al. Oral cytokine gene therapy against murine tumor using attenuated Salmonella typhimurium. Int J Cancer, 2001, 94(3):
438~443.
[75] Urashima M, Suzuki H, Yuza Y, et al. An oral CD40 ligand gene therapy against lymphoma using attenuated Salmonella typhimurium. Blood, 2000, 95(4): 1258~1263.
[76] Cochlovius B, Stassar MJ, Schreurs MW, et al. Oral DNA vaccination: antigen uptake and presentation by dendritic cells elicits protective immunity. Immunol Lett, 2002, 80(2): 89-96.
[77] Foltis BA,Sahar DA,Kim AS,et al.Cyclooxygenase-2 inhibition augments the hepatic antitumor effect of oral Salmonella typhimurium in a model of mouse metastatic colon cancer. Dis Colon Rectum, 2002, 45(8): 1023~1028.
[78] Tacket CO, Sztein MB, Wasseman SS ,et al . Phase 2 clinical trial of attenuated Salmonella enterica serovar typhi oral live vector vaccine CVD 908-htrA in U.S volunteers. Infect Immun ,2000 ,68(3) :1196~1201.
[79] Chow YH ,Huang WL ,Cli WK, et al . Improvement of hepatitis B virus DNA vaccines by plasmids coexpressing hepatitis B surface antigen and interleukin-2. J Virol, 1997, 71(1) : 169~178.
[80] Barouch DH ,Santra S ,Steenbeke TD ,et al . Augmentation and suppression of immune responses to an HIV-1 DNA vaccine by plasmid cytokine/ Ig administration. J Immunol, 1998, 161: 1875~1882.
[81] Chow YH, Chiang BL, Lee YL, et al. Development of Th1 and Th2 populations and the nature of immune responses to hepatitis B virus DNA vaccines can be modulated by codelivery of various cytokine genes. J Immunol, 1998, 160 (3) : 1320~1329.
[82] Kim JJ, Ayyavoo V, Bagarazzi ML et al . In vivo engineering of a cellular immune response by coadministration of IL-12 expression vetor with a DNA immunogen. J Immunol, 1997, 158(2): 816~826.
[83] Tsuji T, Hamajima K, Fukushima J, et al . Enhancement of cell mediated immunity against HIV-1 induced by coinoculation of plasmid encoded HIV-l antigen with plasmid expressing IL-12. J Immunol , 1997, 158(8) : 4008~4013.
[84] Xiang Z, Ertl HC. Manipulation of the immune response to a plasmid-encoded viral antigen by coinoculation with plasmids expressing cytokines. Immunity, 1995, (2) : 129~135.
[85] Somasundaram C, Takamatsu H, Andreoni C, et al. Enhanced protective response and immuno adjuvant effects of porcine GM-CSF on DNA vaccination of pigs against Aujeszky’s disease virus. Vet Immunol Immunopathol, 1999, 70 (3~4) :277~287.
[86] Geissler M, Gesien A, Tokushige K, et al. Enhancement of cellular and humoral immune responses to hepatitis C virus core protein using DNA-based vaccines augmented with cytokines-expressing plasmids. J Immunol, 1997, 158 (3) :1231~1237.
[87] Nobiron I, Thompson I, Brownlie J, et al. Cytokine adjuvancy of BVDV DNA vaccine enhances both humoral and cellular immune responses in mice. Vaccine, 2001, 19 (30) 4226~4235.
[88] Lim YS, Kang BY, Kim EJ et al. Potentiation of antigen-specific, Th1 immune responses by multiple DNA vaccination with an ovalbumin/ interferon-gamma hybrid construct . Immunology, 1998, 94(2): 135~141.
[89] Xiang ZQ, He Z, Wang Y, et al. The effect of interferon-gamma on genetic immunization. Vaccine ,1997 ,15(8) :896~898.
[90] Kim SH, Cho D, Hwang SY, et al. Efficient induction of antigen-specific T helper type 1-mediated immune responses by intramuscular injection with ovalbumin/interleukin-18 fusion DNA. Vaccine ,2001 ,19 (30) :4107~4114.
[91] Billaut-Mulot O, Idziorek T, Loyens M, et al. Modulation of cellular and humoral immune responses to a multiepitopic HIV-1 DNA vaccine by interleukin-18
DNA immunization/viral protein boost. Vaccine, 2001, 19 (20-22) :2803~2811.
[92] Kim SH ,Cho D , Kim TS. Induction of in vivo resistance to Mycobacteri um avi um infection by intramuscular injection with DNA encoding interleukin-18. Immunology ,2001 ,102 (2) :234~241.
[93] Dupre L, Kremer L, Wolowczuk I, et al. Immunostimulatory effect of IL-18-encoding plasmid in DNA vaccination against murine Schistosoma mansoni infection. Vaccine, 2001, 19(11-12): 1373~1380
[94] Hanlon L, Argyle D, Bain D, et al. Feline leukemia virus DNA vaccine efficacy is enhanced by coadministration with interleukin-12(IL-12) and IL-18 expression vectors. J Virol, 2001, 75 (18) :8424~8433.
[95] Kim JJ, Yang JS, Dang K, et al. Engineering enhancement of immune responses to DNA-based vaccines in a prostate cancer model in rhesus macaques through the use of cytokine gene adjuvants. Clin Cancer Res, 2001, 7(Suppl 3) :882s~889s.
[96] Sin JI, Kim JJ, Boyer ID, et al. In vivo modulation of vaccine induced immune responses toward a Th1 phenotype increases potency and vaccine effectiveness in a herpes simplex virus type 2 mouse model. J Virol, 1999, 73 (1) :501~509.
[97] Maecker HT, Hansen G, Walter DM, et al. Vaccination with allergen-IL-18 fusion DNA protects against, and reverses established ,airway hyperreactivity in a murine asthma model. J Immunol , 2001, 166 (2) :959~965.
[98] Kim JJ, Simbiri KA, Sin JI, et al. Cytokine molecular adjuvants modulate immune responses induced by DNA vaccine constructs for HIV-1 and SIV. J Interferon Cyt Res ,1999 ,19 (1) :77~84.
[99] Hoshino J, Naganuma F, Nagai R. Ventricular fibrillation triggered by a ruptured sinus of Valsalva aneurysm. Heart, 1998, 80 (2) :203~204.
[100] Ishii KJ, Weiss WR, Ichino M, et al. Activity and safety of DNA plasmids encoding IL-4 and IFN gamma. Gene Ther, 1999, 6 (2) :237~244.
[101] Geissler M, Gesien A, Tokushige K, et al. Enhancement of cellular and humoral immune responses to hepatitis C virus core protein using DNA-based vaccines augmented with cytokines -expressing plasmids. J Immunol, 1997, 158 (3) : 1231~1237.
[102] Burger JA, Mendoza RB, Kipps TJ. Plasmids encoding granulocyte-macrophage colony-stimulating factor and CD154 enhance the immune response to genetic vaccines. Vaccine, 2001, 19 ( 15216 ): 2181~2189.
[103] Flo J, Tisminetzky S, Baralle F. Modulation of the immune response to DNA vaccine by codelivery of costimulatry molecules .Immunology, 2000, 100(6) : 2659~ 2671
[104] Krieg AM, Yi AK, Matson S , et al . CpG motifs in bacterial DNA trigger direct B-cell activation. Nature, 1995 , 374 (6522) : 546 ~549.
[105] Sato Y, RomanM, Tighe H, et al. Immunostimulatory DNA sequences necessary for effective intradermal gene immunization. Science, 1996, 273(5273): 352~354.
[106] Klinman DM ,Barnhart KM , Conover J. CpG motif as immune adjuvants. Vaccine, 1999, 17(1): 19~25.
[107] Cheng L, Ziegelhofler PR, Yang NS. In vivo promoter activity and transgene expression in mammalian somatic tissues evaluated by using particle bombardment. Proc Natl Acad Sci USA, 1993, 90(10): 4455~4459.
[108] Wolff JA, Ludtke JJ, Acsadi G. Long-term persistence of plasmid DNA and foreign gene expression in mouse muscle. Hum Mol Genet, 1992, 1(6): 363~369.
[109]Chaplin PJ ,De Rose R ,Boyle JS , et al. Targeting improves the efficacy of a DNA vaccine against Corynebacterium pseudotuberculosis in sheep. Infect Immun ,
1999, 67(12) : 6434 ~6438
[110]Lew AM, Brady BJ, Boyle BJ. Site-directed immune responses in DNA vaccines encoding ligand-antigen fusions. Vaccine, 2000, 18 (16): 1681~1685
[111] Cregg JM, Cereghino JL, Shi J, et al. Recombinant protein expression in Pichia pastoris. Mol Biotechnol. 2000 ,16(1):23~52.
[112] Cereghino JL, Cregg JM. Heterologous protein expression in the methylotrophic yeast Pichia pastoris.FEMS Microbiol Rev. 2000,24(1):45~66.
[113]A Manual of Methods for Expression of Recombinant Proteins Using pPICZ and pPICZαin Pichia pastoris.
[114]华慧,周思翔,王正荣. 外源基因在巴斯德毕赤酵母中的表达。国外医学生物医学工程分册,2003. 26(3) :112～117.
[115]朱剑昆,许志详,黄伟达,等. 人重组白细胞介素11在毕氏酵母系统中的表达及纯化中国医学科学院学报,2001 ,23 (2) :127～131.
[116]马骊, 王小宁, 张智清,等. VEGF165 cDNA在酵母中的表达、纯化及其生物学活性研究。细胞与分子免疫学,2001 ,17(1) :24～28.
[117]官孝群,王跃祥,吴良成,等. 血管生成抑制因子K4K5 cDNA基因的克隆及其在毕赤酵母中的表达,生物工程学报,2001 ,17 (2) :126～130.
[118]阎锡蕴,汤健,刁爱坡. 抗IV型胶原酶单链抗体在毕赤酵母中分泌表达,微生物学通报,2001 ,28 (1) :48～52.
[119]Cereghino GP, Cereghino JL, Ilgen C, et al. Production of recombinant proteins in fermenter cultures of the yeast Pichia pastoris.Curr Opin Biotechnol, 2002,13(4) :329～332.
[120]熊爱生,彭日荷,李贤,等. 信号肽序列对毕赤酵母表达外源蛋白质的影响,生物化学与生物物理学报,2003 ,35(2) :154～160.
[121]Sreekrishna K, Brankamp RG, Kropp KE, et al. Strategies for optimal synthesis and secretion of heterologous proteins in the methylotrophic yeast Pichia pastoris. Gene, 1997, 190(1): 55~62.
[122]Sambrook J, Fritsch EF, and Maniatis T. Molecular cloning. A laborator manual. 2nd ed. Cold Spring Harbor Laboratory Press, 1989.
[123].徐兵.产毒性大肠杆菌口服活菌疫苗的初步研究[博士研究论文].第一军医大学.1999,43~44.
[124] Christoph S,Mason WS. Hepatitis B virus biology. Microbiology and Molecular Biology Reviews,2000,64(l):51~68
[125] Haro I., Pinto, R.M., Gonzalez-Dankaart, J.F., Perez, J.A., Reig, F., Bosch, A., 1995. Anti-hepatitis A virus antibody response in mice elicited by different forms of a synthetic VP1 peptide.Microbiol. Immunol. 39(7): 485~490
[126] Pinto RM, Gonzalez-Dankaart JF, Sanchez F, et al. Immunogenicity of a synthetic peptide bearing a new epitope of hepatitis A virus. FEBS Lett, 1998, 438:106~110
[127] Wolff JA, Malone RW, Williams P, et al. Direct gene transfer into mouse muscle in vivo. Science 1990, 247(4949 Pt 1): 1465～1468
[128] Gentschev I, Dietrich G, Spreng S, et al. Recombinant attenuated bacteria for the delivery of subunit vaccines. Vaccine, 2001,19 (17~19) : 2621~2628.
[129] Darji A , zur Lage S, Garbe AI, et al. Oral delivery of DNA vaccines using attenuated Salmonella typhimmurium as carrier. FEMS Immunol Med Microbioll, 2000, 27 (4) : 341~349.
[130] Jain V, M ekalano s JJ. Use of lambda phage S and R gene products in an inducible lysis system for vibrio cholerae-and Salmonella enterica serovar typhimurium-based DNA vaccine delivery system s. Infect Immun, 2000, 68 (2) : 986~989.
[131] Galen JE, Zhao L, Chinchilla M et al. Adaptation of the endogenous Salmonella enterica serovar Typhi clyA-encoded hemolysin for antigen export enhances the immunogenicity of anthrax protective antigen domain 4 expressed by the attenuated live-vector vaccine strain CVD 908-htrA.Infect Immun. 2004 , 72(12):7096~106.
[132] Agnieszka Wyszynska, Anna Raczko, Malgorzata et al.Oral immunization of chickens with avirulent Salmonella vaccine strain carrying C.jejuni 72Dz/92 cjaA gene elicits specific humoral immune responses associated with protection against challenge with wild-type Campylobacter.vaccine, 2004,22, 1379~1389
[133] Edman JC, Hallewell RA, Valenzuela P, et al. Synthesis of hepatitis B surface and core antigens in E.coli. Nature 291 (1981) 503~506.
[134]Charnay P,Gervais M, Louise A, et al. Biosynthesis of hepatitis B virus surface antigen in E.coli. Nature 286 (1980) 893~895.
[135]成军,杨守纯。现代肝炎病毒分子生物学,1999,人民军医出版社
[136] Kaufman RJ. Overview of vector design for mammalian gene expression.Methods Mol Biol. 1997, 62:287~300.
[137] Conradt HS, Nimtz M, Dittmar KE, et al. Expression of human interleukin-2 in recombinant baby hamster kidney, Ltk-, and Chinese hamster ovary cells. Structure of O-linked carbohydrate chains and their location within the polypeptide. J Biol Chem. 1989, 15, 264(29):17368~17373.
[138] Rotondaro L, Mazzanti L, Mele A, et al. High-level expression of a cDNA for human granulocyte colony-stimulating factor in Chinese hamster ovary cells. Effect of 3'-noncoding sequences.Mol Biotechnol. 1997,7(3):231~240.
[139] Kim CH, Oh Y, Lee TH.Codon optimization for high-level expression of human erythropoietin (EPO) in mammalian cells.Gene. 1997, 199(1~2):293~301.
[140] Cockett MI, Bebbington CR, Yarranton GT. High level expression of tissue inhibitor of metalloproteinases in Chinese hamster ovary cells using glutamine
synthetase gene amplification.Biotechnology (N Y). 1990, 8(7):662~667.
[141] 来大志,齐连权,于长明。改造中国仓鼠卵巢细胞,生物工程学报,2002,18(4):415~419
[142] Verma R, Boleti E, George AJ. Antibody engineering: comparison of bacterial, yeast, insect and mammalian expression systems. J Immunol Methods. 1998 , 216(1-2):165~181.
[143] 刘文军,杨芙蓉,阮力等,三种病毒启动子在中国地鼠卵巢(CHO)细胞中表达活性的比较,病毒学报,1997,13(2):164~168
[144] Wickens M, Stephenson P. Role of the conserved AAUAAA sequence:four AAUAAA point mutants prevent messenger RNA 3′end formation. Science, 1984, 26(4678):1045~1051
[145] Sadofsky M, Connelly S, Manley JL, et al. Identification of a sequence element on the 3'side of AAUAAA which is necessary for simian virus 40 late mRNA 3′-end processing. Mol Cell Biol,1985,5(10):2713~2719
[146] Huang MT, Gorman CM. Intervening sequences increase efficiency of RNA 3′processing and accumulation of cytoplasmic RNA. Nucleic Acid. Res.1990. 18(4): 937~947
[147] Shaw G, Kamen R. A conserved AU sequence from the 3′untranslated region of GM-CSF mRNA mediates selective mRNA degradation. Cell,1986, 46(5) :659~667
[148] Whitton JL, Rodriguez F, Zhang J,et al. DNA immunization :mechanistic studies. Vaccine, 1999 , 17(13-14):1612～1619
[149] Sirard JC, Niedergang F, Kraehenbuhl JP. Live attenuated salmonella: a paradigm of mucosal vaccines. Immunol Rev, 1999, 171 :5～26
[150]陈东立,马清钧. 表达霍乱CT2B 和LPS2O抗原的鼠伤寒菌苗株的构建. 生物工程学报, 1997, 13(1):47~52.
[151]Formal S B , Baron L S , Kopecko D J , et al. Construction of a potential bivalent vaccine strain: introduction of Shigella sonnei from Ⅰantigen genes into the galE Salmonella typhimurium Ty21a typhoid vaccine strain . Infect Immune , 1981 , 34 :746~750.
[152]Hone D M, Harris A M, Chatfield S , et al. Construction of genetically defined double aro mutants of Salmonella typhimurium . Vaccine , 1991 , 9(11): 810~816.
[153]Attridge S R , Davies R , LaBrooy J T. Oral delivery of foreign antigens by attenuated Salmonella : consequences of prior exposure to the vector strain. Vaccine, 1997, 15(2) : 155~162.
[154] 江文正,金宁一。表达HIV-1结构蛋白靶细胞的制备及鉴定。中国生物制品学杂志,2003,16(2):70~71.
[155] Okamura H, Tsutsi H, Komatsu T, et al. Cloning of a new cytokine that induces IFN-gamma production by T cells. Nature,1995 , 378(6552):88~91.
[156] Hartikka J, Sawdey M, Jensen FC, et al. An improved plasmid DNA expression vector for direct injection into skeletal muscle. Human Gene Ther, 1996, 7(10):1205～1217
[157] Haddad D, Ramp rakash J , SedegahM , et al, Plasmid vaccine expressing granulocyte macrophage colony stimulating factor attracts infiltrates including immature dendritic cdeel into injected muscles. J Immuno l, 2000, 165: 3772~3781.
[158] Biet F, Locht C, Kremer L. Immunoregulatory functions of interleukin 18 and its role in defense against bacterial pathogens. J Mol Med. 2002 , 80(3):147~162.
[159] Scheerlinck JY.Genetic adjuvants for DNA vaccines. Vaccine. 2001, 19 (17-19): 2647~ 2656.
[2] Emini EA, Hughes JV, Perlow DS, et al. Induction of hepatitis A virus-neutralizing antibody by a virus-specific synthetic peptide. J Virol, 1985, 55(3): 836~839.
[3] Wheeler CM, Robertson BH, Van Nest G, et al. Structure of the hepatitis A virion: peptide mapping of the capsid region. J Virol, 1986, 58(2):307~313.
[4] Bosch A, Gonzalez-Dankaart JF, Haro I, et al. A new continuous epitope of hepatitis A virus. J Med Virol, 1998, 54(2): 95~102.
[5] Haro I, Perez S, Garcia M, Chan WC, et al.Liposome entrapment and immunogenic studies of a synthetic lipophilic multiple antigenic peptide bearing VP1 and VP3 domains of the hepatitis A virus: a robust method for vaccine design. FEBS Letters, 2003, 540: 133 ~140.
[6] Sun Z, Ming L, Zhu X, et al. Prevention and control of hepatitis B in China. J Med Virol, 2002, 67(3): 447~450.
[7] Zuckerman JN,Zuckerman AJ. Current topics in hepatitis B. J Infect, 2000, 41(2):130~136.
[8] Mackay P, Pasek M, Magazin M, et al. Production of immunologically active surface antigens of hepatitis B virus by Escherichia coli. Proc Natl Acad Sci USA, 1981,78(7): 4510~4514.
[9] Fujisawa Y, Ito Y, Sasada R, et al . Direct expression of hepatitis B surface antigen gene in E. coli. Nucleic Acids Res,1983, 11(11): 3581~3591.
[10] Tiollais P, Christine P, Dejean A. The hepatitis B virus. Nature, 1985, 371(6037): 489~495.
[11] Smith KM, Eaton AD, Finlayson LM, et al . Oral tolerance. Am J Respir Crit Care Med, 2000, 162(4 Pt 2): S175~178.
[12] Ogra PL, Faden H, Welliver RC. Vaccination strategies for mucosal immune responses. Clin Microbiol Rev, 2001, 14 : 430~445.
[13] Davis HL, McCluskie MJ, Gerin JL, et al. DNA vaccine for hepatitis B: evidence for immunogenicity in chimpanzees and comparison with other vaccines . Proc Natl Acad Sci USA, 1996, 93(14):7213~7218
[14] 冯子健,封秀红,叶莹,等。不同剂量国产重组酵母乙肝疫苗对成人免疫效果观察。中国公共卫生,2002,18 (2):215~216。
[15] Flehmig B, Heinricy U, Pfisterer M. Simultaneous vaccination for hepatitis A and B.J Infect Dis. 1990,161(5): 865~868.
[16] Papaevangelou G. Current combined vaccines with hepatitis B. Vaccine, 1998, 16 (Suppl ) : S69-72.
[17] Thoelen S, Van Damme P, Leentvaar-Kuypers A, et al. The first combined vaccine against hepatitis A and B: an overview. Vaccine, 1999, 17 (13~14): 1657~1662.
[18] Burgess MA,Rodger AJ,Waite SA,et al. Comparative immunogenicity and safety of two dosing schedules of a combined hepatitis A and B vaccine in healthy adolescent volunters: an open, randomised study. Vaccine, 2001,19:4835~4841.
[19] Kallinowski B, Bock HL, Clemens R, et al. Immunogenicity and reactogenicity of a combined hepatitis A/B candidate vaccine :first results. Liver, 1996, 16(4) :271~273.
[20] Leroux-Roels G, Moreau W, Desombere I, et al. Safety and immunogenicity of a combined hepatitis A and hepatitis B vaccine in young healthy adults. Scand J Gastrogenterol, 1996,31 (10) : 1027~1031.
[21] Nakayama K, Kelly SM, Curtiss R Ⅲ. Construction of an asd+ expression-cloning vector: stable maintenance and high level expression of cloned
genes in a Salmonella vaccine strain. Bio/Technology, 1988, 6: 693~697.
[22] Tacket CO, Kelly SM, Schodel F, et al. Safety and immunogenicity in humans of an attenuated salmonella typhi vaccine vector strain expressing plasmid-encoded hepatitis B antigens stabilized by the Asd-balanced lethal vector system. Infect Immun, 1997, 65(9):3381~3385
[23] Germanier R, Fuer E. Isolation and characterization of Gal E mutant Ty 21a of Salmonella typhi: a candidate strain for a live, oral typhoid vaccine. J Infect Dis. 1975, 131(5): 553~558.
[24] Stocker BA,Auxotrophic Salmonella typhi as live vaccine.Vaccine.1988, 6(2): 141~145.
[25] Hone D, Morona R, Attridge S, et al. Construction of defined galE mutants of Salmonella for use as vaccines. J Infect Dis, 1987, 156(1): 167~174.
[26] Curtiss R 3 rd, Kelly SM. Salmonella typhimurium deletion mutants lacking adenylate cyclase and cyclic AMP receptor protein are avirulent and immunogenic.Infect Immun. 1987, 55(12): 3035~3043.
[27] McFarland WC, Stocker BA. Effect of different purine auxotrophic mutations on mouse-virulence of a Vi-positive strain of Salmonella dublin and of two strains of Salmonella typhimurium. Microb Pathog, 1987, 3(2):129~141.
[28] Hohmann EL, Oletta CA, Miller SI. Evaluation of a phoP/phoQ-deleted, aroA-deleted live oral Salmonella typhi vaccine strain in human volunteers.Vaccine, 1996,14(1):19~24.
[29] Edwards MF,Stocker BA. Construction of delta aroA his delta pur strains of Salmonella typhi.J Bacteriol, 1988, 170(9): 3991~3995.
[30] O'callachan D, Maskell D, Liew FY, et al. Characterization of aromatic-and purine-dependent Salmonella typhimurium: attenuation, persistence and ability to induce protective immunity in BALB/c mice.Infect Immun , 1988 ,56 (2):419~423.
[31] Galan JE, Nakayama K, Curtiss R 3rd, et al. Cloning and characterization of the asd gene of Salmonella typhimurium: use in stable maintenance of recombinant plasmids in Salmonella vaccine strains.Gene, 1990, 94(1): 29~35
[32] Lowe DC, Savidge TC, Pickard D, et al. Characterization of candidate live oral Salmonella typhi vaccine strains harboring defined mutations in aroA, aroC and htrA. Infect Immun, 1999, 67(2): 700~707.
[33] Heithoff DM, Sinsheimer RL, Low DA, et al. An essential role for DNA adenine methylation in bacterial virulence.Science, 1999, 284(5416): 967~970.
[34] Curtiss R 3rd, Hassan J. Nonrecombinant and recombinant avirulent Salmonella vaccines for poultry. Vet immunol and Immunopathol, 1996, 54(1~4), 365~372.
[35] Ahmer BM, van Reeuwijk J, Watson PR, et al. Salmonella SirA is a global regulator of genes mediating enteroathogenesis. Mol.Microbiol, 1999, 31(3):971~982.
[36] Clements JD, E1-Morshidy S . Construction of a potential live oral bivalent vaccine for typhoid fever and cholera-Escherichia coli-related diarrheas. Infect Immun, 1984, 46(2):564~569.
[37] Giron JA, Xu JG, Gonzalez CR, et al. Simultaneous expression of CFA/I and CS3 colonization factor antigens of enterotoxigenic Escherichia coli by delta aroC, delta aroD Salmonella typhi vaccine strain CVD 908.Vaccine, 1995, 13(10):939~946.
[38] Valentine PJ, Devore BP, Heffron F. Identification of three highly mice than a prototypical aroA mutant. Infection and Immunity, 1998, 66(7): 3378~3383.
[39] Miller SI,Mekalanos JJ, Pulkkinen WS. Salmonella vaccines with mutations in the phoP virulence regulon. Res.Microbiol, 1990, 141(7~8): 817~821.
[40] Levine MM, Ferreccio C, Black RE, et al. Large-scale field trial of Ty21a live oral typhoid vaccine in enteric-coated capsule formulation. Lancet, 1987, 1(8541): 1049~1052.
[41] Chatfield SN ,Charles IG, Makoff AJ, et al . Use of the nirB promoter to direct the stable expression of heterologous antigens in Salmonella oral vaccine strains: development of a single-dose oral tetanus vaccine. Biotechnology, 1992, 10 (8): 888~ 892.
[42] Everest P, Frankel G, Li J, Lund P, et al. Expression of lacZ from the htrA, nirB and groE promoters in a Salmonella vaccine strain: influence of growth in mammalian cells. FEMS Microbiol Lett, 1995, 126(1):97~101.
[43] Huang Y, Hajishengallis G, Michalek SM. Construction and characterization of a Salmonella enterica serovar typhimurium clone expressing a salivary adhesin of Streptococcus mutants under control of the anaerobically inducible promoter. Infect Immun , 2000 , 68(3) :1549~1556.
[44] Oxer MD, Benthey CM, Doyle JG, et al . High level heterologous expression in E. coli using the anaerobically activated nirB promoter. Nucl Acids Res, 1991, 19(11) :2889~2992.
[45] Pasetti MF, Anderson RJ, Noriega FR, et al. Attenuated deltaguaBA Salmonella typhi vaccine strain CVD 915 as a live vector utilizing prokaryotic or eukaryotic expression systems to deliver foreign antigens and elicit immune responses. Clin Immunol, 1999, 92 (1): 76~89.
[46] Hone D, Attridge S, van den Bosch L, et al. A chromosomal integration system for stabilization of heterologous genes in Salmonella based vaccine strains.Microb Pathog, 1988, 5(6): 407~418.
[47] Strugnell RA, Maskell D, Fairweather N, et al. Stable expression of foreign antigens from the chromosome of Salmonella typhimurium vaccine strains.Gene, 1990, 88(1):57~63.
[48] Flynn JL, Weiss WR, Norris KA. Generation of a cytotoxic T-lymphocyte response using a Salmonella antigen-delivery system. Mol Microbiol, 1990, 4(12):
2111~2118.
[49] Morona R, Morona JK, Considine A, et al. Construction of K88-and K99-expressing clones of Salmonella typhimurium G30: immunogenicity following oral administration to pigs.Vaccine, 1994 , 12(6):513~517
[50] Redman TK, Harmon CC, Michalek SM.Oral immunization with recombinant Salmonella typhimurium expressing surface protein antigen A (SpaA) of Streptococcus sobrinus: effects of the Salmonella virulence plasmid on the induction of protective and sustained humoral responses in rats. Vaccine, 1996, 14(9): 868~878.
[51] Woo PC, Wong LP, Zheng BJ, et al. Unique immunogenicity of hepatitis B virus DNA vaccine presented by live-attenuated Salmonella typhimurium. Vaccine, 2001, 19 (20-22): 2945~2954.
[52] 陈东立,马清钧。表达霍乱CT-B 和LPS-O 抗原的鼠菌苗株的构建.生物工程学报,1997,13(l):47~52。
[53] Dunstan SJ, Simmons CP, Strugnell RA.Comparison of the abilities of different attenuated Salmonella typhimurium strains to elicit humoral immune responses against a heterologous antigen. Infect Immun, 1998, 66(2): 732~740.
[54] Fastad IN, Halstense TS, fausa O, et al. Heterogeneity of M-cell-associated B and T cells in human Peyers patches. Immunology, 1994, 83(3) :457~464.
[55] Clark MA, Jepson MA, Simmons NL, et al. Selective binding and transcytosis of Ulex europaeus 1 lectin by mouse Peyer's patch M-cells in vivo.Cell Tissue Res, 1995, 282(3):455~461.
[56] Jones BD, Ghori N, Faikow S.Salmonella typhimurium initiates murine infectin by penetrating and destroying the specialized epithelial M cells of the Peyer's patches. J ExP Med, 1994, 180(1):15~23
[57] Jensen VB,Harty JT, Jones BD. Interactions of the Invasive pathogens Salmonella typhimurium,Listeria monocytogenes, and Shigella flexneri with M Cells
and Murine Peyer’s Patches. Infect and Immun, 1998, 66(8) 3758~3766 .
[58] Hopkins SA, Niedergang F,Corhesy-Theulaz IE, et al. A recombinant Salinonella typhimurium vaccine strain is taken up and survives within murine Peyer’s Patch dendritic cells. Cell Microbiol, 2000, 2(1):59~68.
[59] Rescigno M.In Dendritic Cell:Biology and clinical application (ed.Thomson, MLa A.) 403~419 (Academic Press, San Diego, CA.1999)
[60] Hofer S, Rescigno M, Granucci F, et al . Differential activation of NF-kappa B subunits in dendritic cells in response to Gram-negative bacteria and to lipopolysaccharide. Microbes Infect, 2001, 3 (4) : 259~265.
[61] Giannasca PJ, Neutral MR. Interactions of microorganisms with intestinal M cells: mucosal invasion and induction of secretory immunity.Infect Agents Dis, 1993, 2(4): 242~248.
[62] Yrlid U, Wick MJ.Salmonella-induced apotosis of infected macrophages results in presentation of a bacteria-encoded antigen after uptake by bystander dendritic cells.J ExP Med, 2000, 191(4): 613~624.
[63] Figueroa-Bossi N, Uzzau S, Maloriol D, et al.Variable assortment of prophages provides a transferable repertoire of pathogenic determinants in Salmonella. Mol Microbiol. 2001, 39 (2): 260~271.
[64] Sznol M, Lin SL, Bermudes D, et al. Use of preferentially replicating bacterial for the treatment of cancer. J Clin invest, 2000, 105(8):1027~1030.
[65] Gentschev I, Dietrich G, Spreng S, et al. Use of the alpha-hemolysin secretion system of Escherichia coli for antigen delivery in the Salmonella typhi Ty21a vaccine strain. Int J Med Microbiol. 2004, 294(6):363~371.
[66] Stabel TJ, Mayfield JE, Tabatabai LB. Oral immunization of mice with attenuated Salmonella typhimurium containing a recombinant plasmid which codes for production of a 31-kilodalton protein of Brucella abortus.Infect Immun. 1990, 58(7):
2048~2055.
[67] Roland K, Karaca K, Sizemore D. Expression of Escherichia coli antigens in Salmonella typhimurium as a vaccine to prevent airsacculitis in chickens. Avian Dis. 2004,48(3):595~605.
[68] Baud D, Ponci F, Bobst M, Improved efficiency of a Salmonella-based vaccine against human papillomavirus type 16 virus-like particles achieved by using a codon-optimized version of L1. J Virol, 2004, 78(23):12901-12909.
[69] Woo PC, Wong LP, Zheng BJ, Yuen KY. Unique immunogenicity of hepatitis B virus DNA vaccine presented by live-attenuated Salmonella typhimurium.Vaccine,2001,19(20~22), 2945~2954.
[70] Karpenko LI, Nekrasova NA, Ilyichev AA,Comparative analysis using a mouse model of the immunogenicity of artificial VLP and attenuated Salmonella strain carrying a DNA-vaccine encoding HIV-1 polyepitope CTL-immunogen. Vaccine. 2004, 22 (13-14): 1692~1699.
[71] Pogonka T, Klotz C, Kovacs F, et al. A single dose of recombinant Salmonella typhimurium induces specific humoral immune responses against heterologous Eimeria tenella antigens in chicken. Int J Parasitol. 2003, 33(1):81-88.
[72] Stager S, Gottstein B, Muller N. Systemic and local antibody response in mice induced by a recombinant peptide fragment from Giardia lamblia variant surface protein (VSP) H7 produced by a Salmonella typhimurium vaccine strain. Int J Parasitol. 1997, 27(8): 965~971
[73] Sadoff JC, Ballou WR, Baron LS, et al. Oral Saimonella typhimurium vaccine expressing circumsporozoite protein protects against malaria.Science, 1988, 240(4850): 336~338
[74] Yuhua L, Kunyuan G, Hui C, et al. Oral cytokine gene therapy against murine tumor using attenuated Salmonella typhimurium. Int J Cancer, 2001, 94(3):
438~443.
[75] Urashima M, Suzuki H, Yuza Y, et al. An oral CD40 ligand gene therapy against lymphoma using attenuated Salmonella typhimurium. Blood, 2000, 95(4): 1258~1263.
[76] Cochlovius B, Stassar MJ, Schreurs MW, et al. Oral DNA vaccination: antigen uptake and presentation by dendritic cells elicits protective immunity. Immunol Lett, 2002, 80(2): 89-96.
[77] Foltis BA,Sahar DA,Kim AS,et al.Cyclooxygenase-2 inhibition augments the hepatic antitumor effect of oral Salmonella typhimurium in a model of mouse metastatic colon cancer. Dis Colon Rectum, 2002, 45(8): 1023~1028.
[78] Tacket CO, Sztein MB, Wasseman SS ,et al . Phase 2 clinical trial of attenuated Salmonella enterica serovar typhi oral live vector vaccine CVD 908-htrA in U.S volunteers. Infect Immun ,2000 ,68(3) :1196~1201.
[79] Chow YH ,Huang WL ,Cli WK, et al . Improvement of hepatitis B virus DNA vaccines by plasmids coexpressing hepatitis B surface antigen and interleukin-2. J Virol, 1997, 71(1) : 169~178.
[80] Barouch DH ,Santra S ,Steenbeke TD ,et al . Augmentation and suppression of immune responses to an HIV-1 DNA vaccine by plasmid cytokine/ Ig administration. J Immunol, 1998, 161: 1875~1882.
[81] Chow YH, Chiang BL, Lee YL, et al. Development of Th1 and Th2 populations and the nature of immune responses to hepatitis B virus DNA vaccines can be modulated by codelivery of various cytokine genes. J Immunol, 1998, 160 (3) : 1320~1329.
[82] Kim JJ, Ayyavoo V, Bagarazzi ML et al . In vivo engineering of a cellular immune response by coadministration of IL-12 expression vetor with a DNA immunogen. J Immunol, 1997, 158(2): 816~826.
[83] Tsuji T, Hamajima K, Fukushima J, et al . Enhancement of cell mediated immunity against HIV-1 induced by coinoculation of plasmid encoded HIV-l antigen with plasmid expressing IL-12. J Immunol , 1997, 158(8) : 4008~4013.
[84] Xiang Z, Ertl HC. Manipulation of the immune response to a plasmid-encoded viral antigen by coinoculation with plasmids expressing cytokines. Immunity, 1995, (2) : 129~135.
[85] Somasundaram C, Takamatsu H, Andreoni C, et al. Enhanced protective response and immuno adjuvant effects of porcine GM-CSF on DNA vaccination of pigs against Aujeszky’s disease virus. Vet Immunol Immunopathol, 1999, 70 (3~4) :277~287.
[86] Geissler M, Gesien A, Tokushige K, et al. Enhancement of cellular and humoral immune responses to hepatitis C virus core protein using DNA-based vaccines augmented with cytokines-expressing plasmids. J Immunol, 1997, 158 (3) :1231~1237.
[87] Nobiron I, Thompson I, Brownlie J, et al. Cytokine adjuvancy of BVDV DNA vaccine enhances both humoral and cellular immune responses in mice. Vaccine, 2001, 19 (30) 4226~4235.
[88] Lim YS, Kang BY, Kim EJ et al. Potentiation of antigen-specific, Th1 immune responses by multiple DNA vaccination with an ovalbumin/ interferon-gamma hybrid construct . Immunology, 1998, 94(2): 135~141.
[89] Xiang ZQ, He Z, Wang Y, et al. The effect of interferon-gamma on genetic immunization. Vaccine ,1997 ,15(8) :896~898.
[90] Kim SH, Cho D, Hwang SY, et al. Efficient induction of antigen-specific T helper type 1-mediated immune responses by intramuscular injection with ovalbumin/interleukin-18 fusion DNA. Vaccine ,2001 ,19 (30) :4107~4114.
[91] Billaut-Mulot O, Idziorek T, Loyens M, et al. Modulation of cellular and humoral immune responses to a multiepitopic HIV-1 DNA vaccine by interleukin-18
DNA immunization/viral protein boost. Vaccine, 2001, 19 (20-22) :2803~2811.
[92] Kim SH ,Cho D , Kim TS. Induction of in vivo resistance to Mycobacteri um avi um infection by intramuscular injection with DNA encoding interleukin-18. Immunology ,2001 ,102 (2) :234~241.
[93] Dupre L, Kremer L, Wolowczuk I, et al. Immunostimulatory effect of IL-18-encoding plasmid in DNA vaccination against murine Schistosoma mansoni infection. Vaccine, 2001, 19(11-12): 1373~1380
[94] Hanlon L, Argyle D, Bain D, et al. Feline leukemia virus DNA vaccine efficacy is enhanced by coadministration with interleukin-12(IL-12) and IL-18 expression vectors. J Virol, 2001, 75 (18) :8424~8433.
[95] Kim JJ, Yang JS, Dang K, et al. Engineering enhancement of immune responses to DNA-based vaccines in a prostate cancer model in rhesus macaques through the use of cytokine gene adjuvants. Clin Cancer Res, 2001, 7(Suppl 3) :882s~889s.
[96] Sin JI, Kim JJ, Boyer ID, et al. In vivo modulation of vaccine induced immune responses toward a Th1 phenotype increases potency and vaccine effectiveness in a herpes simplex virus type 2 mouse model. J Virol, 1999, 73 (1) :501~509.
[97] Maecker HT, Hansen G, Walter DM, et al. Vaccination with allergen-IL-18 fusion DNA protects against, and reverses established ,airway hyperreactivity in a murine asthma model. J Immunol , 2001, 166 (2) :959~965.
[98] Kim JJ, Simbiri KA, Sin JI, et al. Cytokine molecular adjuvants modulate immune responses induced by DNA vaccine constructs for HIV-1 and SIV. J Interferon Cyt Res ,1999 ,19 (1) :77~84.
[99] Hoshino J, Naganuma F, Nagai R. Ventricular fibrillation triggered by a ruptured sinus of Valsalva aneurysm. Heart, 1998, 80 (2) :203~204.
[100] Ishii KJ, Weiss WR, Ichino M, et al. Activity and safety of DNA plasmids encoding IL-4 and IFN gamma. Gene Ther, 1999, 6 (2) :237~244.
[101] Geissler M, Gesien A, Tokushige K, et al. Enhancement of cellular and humoral immune responses to hepatitis C virus core protein using DNA-based vaccines augmented with cytokines -expressing plasmids. J Immunol, 1997, 158 (3) : 1231~1237.
[102] Burger JA, Mendoza RB, Kipps TJ. Plasmids encoding granulocyte-macrophage colony-stimulating factor and CD154 enhance the immune response to genetic vaccines. Vaccine, 2001, 19 ( 15216 ): 2181~2189.
[103] Flo J, Tisminetzky S, Baralle F. Modulation of the immune response to DNA vaccine by codelivery of costimulatry molecules .Immunology, 2000, 100(6) : 2659~ 2671
[104] Krieg AM, Yi AK, Matson S , et al . CpG motifs in bacterial DNA trigger direct B-cell activation. Nature, 1995 , 374 (6522) : 546 ~549.
[105] Sato Y, RomanM, Tighe H, et al. Immunostimulatory DNA sequences necessary for effective intradermal gene immunization. Science, 1996, 273(5273): 352~354.
[106] Klinman DM ,Barnhart KM , Conover J. CpG motif as immune adjuvants. Vaccine, 1999, 17(1): 19~25.
[107] Cheng L, Ziegelhofler PR, Yang NS. In vivo promoter activity and transgene expression in mammalian somatic tissues evaluated by using particle bombardment. Proc Natl Acad Sci USA, 1993, 90(10): 4455~4459.
[108] Wolff JA, Ludtke JJ, Acsadi G. Long-term persistence of plasmid DNA and foreign gene expression in mouse muscle. Hum Mol Genet, 1992, 1(6): 363~369.
[109]Chaplin PJ ,De Rose R ,Boyle JS , et al. Targeting improves the efficacy of a DNA vaccine against Corynebacterium pseudotuberculosis in sheep. Infect Immun ,
1999, 67(12) : 6434 ~6438
[110]Lew AM, Brady BJ, Boyle BJ. Site-directed immune responses in DNA vaccines encoding ligand-antigen fusions. Vaccine, 2000, 18 (16): 1681~1685
[111] Cregg JM, Cereghino JL, Shi J, et al. Recombinant protein expression in Pichia pastoris. Mol Biotechnol. 2000 ,16(1):23~52.
[112] Cereghino JL, Cregg JM. Heterologous protein expression in the methylotrophic yeast Pichia pastoris.FEMS Microbiol Rev. 2000,24(1):45~66.
[113]A Manual of Methods for Expression of Recombinant Proteins Using pPICZ and pPICZαin Pichia pastoris.
[114]华慧,周思翔,王正荣. 外源基因在巴斯德毕赤酵母中的表达。国外医学生物医学工程分册,2003. 26(3) :112～117.
[115]朱剑昆,许志详,黄伟达,等. 人重组白细胞介素11在毕氏酵母系统中的表达及纯化中国医学科学院学报,2001 ,23 (2) :127～131.
[116]马骊, 王小宁, 张智清,等. VEGF165 cDNA在酵母中的表达、纯化及其生物学活性研究。细胞与分子免疫学,2001 ,17(1) :24～28.
[117]官孝群,王跃祥,吴良成,等. 血管生成抑制因子K4K5 cDNA基因的克隆及其在毕赤酵母中的表达,生物工程学报,2001 ,17 (2) :126～130.
[118]阎锡蕴,汤健,刁爱坡. 抗IV型胶原酶单链抗体在毕赤酵母中分泌表达,微生物学通报,2001 ,28 (1) :48～52.
[119]Cereghino GP, Cereghino JL, Ilgen C, et al. Production of recombinant proteins in fermenter cultures of the yeast Pichia pastoris.Curr Opin Biotechnol, 2002,13(4) :329～332.
[120]熊爱生,彭日荷,李贤,等. 信号肽序列对毕赤酵母表达外源蛋白质的影响,生物化学与生物物理学报,2003 ,35(2) :154～160.
[121]Sreekrishna K, Brankamp RG, Kropp KE, et al. Strategies for optimal synthesis and secretion of heterologous proteins in the methylotrophic yeast Pichia pastoris. Gene, 1997, 190(1): 55~62.
[122]Sambrook J, Fritsch EF, and Maniatis T. Molecular cloning. A laborator manual. 2nd ed. Cold Spring Harbor Laboratory Press, 1989.
[123].徐兵.产毒性大肠杆菌口服活菌疫苗的初步研究[博士研究论文].第一军医大学.1999,43~44.
[124] Christoph S,Mason WS. Hepatitis B virus biology. Microbiology and Molecular Biology Reviews,2000,64(l):51~68
[125] Haro I., Pinto, R.M., Gonzalez-Dankaart, J.F., Perez, J.A., Reig, F., Bosch, A., 1995. Anti-hepatitis A virus antibody response in mice elicited by different forms of a synthetic VP1 peptide.Microbiol. Immunol. 39(7): 485~490
[126] Pinto RM, Gonzalez-Dankaart JF, Sanchez F, et al. Immunogenicity of a synthetic peptide bearing a new epitope of hepatitis A virus. FEBS Lett, 1998, 438:106~110
[127] Wolff JA, Malone RW, Williams P, et al. Direct gene transfer into mouse muscle in vivo. Science 1990, 247(4949 Pt 1): 1465～1468
[128] Gentschev I, Dietrich G, Spreng S, et al. Recombinant attenuated bacteria for the delivery of subunit vaccines. Vaccine, 2001,19 (17~19) : 2621~2628.
[129] Darji A , zur Lage S, Garbe AI, et al. Oral delivery of DNA vaccines using attenuated Salmonella typhimmurium as carrier. FEMS Immunol Med Microbioll, 2000, 27 (4) : 341~349.
[130] Jain V, M ekalano s JJ. Use of lambda phage S and R gene products in an inducible lysis system for vibrio cholerae-and Salmonella enterica serovar typhimurium-based DNA vaccine delivery system s. Infect Immun, 2000, 68 (2) : 986~989.
[131] Galen JE, Zhao L, Chinchilla M et al. Adaptation of the endogenous Salmonella enterica serovar Typhi clyA-encoded hemolysin for antigen export enhances the immunogenicity of anthrax protective antigen domain 4 expressed by the attenuated live-vector vaccine strain CVD 908-htrA.Infect Immun. 2004 , 72(12):7096~106.
[132] Agnieszka Wyszynska, Anna Raczko, Malgorzata et al.Oral immunization of chickens with avirulent Salmonella vaccine strain carrying C.jejuni 72Dz/92 cjaA gene elicits specific humoral immune responses associated with protection against challenge with wild-type Campylobacter.vaccine, 2004,22, 1379~1389
[133] Edman JC, Hallewell RA, Valenzuela P, et al. Synthesis of hepatitis B surface and core antigens in E.coli. Nature 291 (1981) 503~506.
[134]Charnay P,Gervais M, Louise A, et al. Biosynthesis of hepatitis B virus surface antigen in E.coli. Nature 286 (1980) 893~895.
[135]成军,杨守纯。现代肝炎病毒分子生物学,1999,人民军医出版社
[136] Kaufman RJ. Overview of vector design for mammalian gene expression.Methods Mol Biol. 1997, 62:287~300.
[137] Conradt HS, Nimtz M, Dittmar KE, et al. Expression of human interleukin-2 in recombinant baby hamster kidney, Ltk-, and Chinese hamster ovary cells. Structure of O-linked carbohydrate chains and their location within the polypeptide. J Biol Chem. 1989, 15, 264(29):17368~17373.
[138] Rotondaro L, Mazzanti L, Mele A, et al. High-level expression of a cDNA for human granulocyte colony-stimulating factor in Chinese hamster ovary cells. Effect of 3'-noncoding sequences.Mol Biotechnol. 1997,7(3):231~240.
[139] Kim CH, Oh Y, Lee TH.Codon optimization for high-level expression of human erythropoietin (EPO) in mammalian cells.Gene. 1997, 199(1~2):293~301.
[140] Cockett MI, Bebbington CR, Yarranton GT. High level expression of tissue inhibitor of metalloproteinases in Chinese hamster ovary cells using glutamine
synthetase gene amplification.Biotechnology (N Y). 1990, 8(7):662~667.
[141] 来大志,齐连权,于长明。改造中国仓鼠卵巢细胞,生物工程学报,2002,18(4):415~419
[142] Verma R, Boleti E, George AJ. Antibody engineering: comparison of bacterial, yeast, insect and mammalian expression systems. J Immunol Methods. 1998 , 216(1-2):165~181.
[143] 刘文军,杨芙蓉,阮力等,三种病毒启动子在中国地鼠卵巢(CHO)细胞中表达活性的比较,病毒学报,1997,13(2):164~168
[144] Wickens M, Stephenson P. Role of the conserved AAUAAA sequence:four AAUAAA point mutants prevent messenger RNA 3′end formation. Science, 1984, 26(4678):1045~1051
[145] Sadofsky M, Connelly S, Manley JL, et al. Identification of a sequence element on the 3'side of AAUAAA which is necessary for simian virus 40 late mRNA 3′-end processing. Mol Cell Biol,1985,5(10):2713~2719
[146] Huang MT, Gorman CM. Intervening sequences increase efficiency of RNA 3′processing and accumulation of cytoplasmic RNA. Nucleic Acid. Res.1990. 18(4): 937~947
[147] Shaw G, Kamen R. A conserved AU sequence from the 3′untranslated region of GM-CSF mRNA mediates selective mRNA degradation. Cell,1986, 46(5) :659~667
[148] Whitton JL, Rodriguez F, Zhang J,et al. DNA immunization :mechanistic studies. Vaccine, 1999 , 17(13-14):1612～1619
[149] Sirard JC, Niedergang F, Kraehenbuhl JP. Live attenuated salmonella: a paradigm of mucosal vaccines. Immunol Rev, 1999, 171 :5～26
[150]陈东立,马清钧. 表达霍乱CT2B 和LPS2O抗原的鼠伤寒菌苗株的构建. 生物工程学报, 1997, 13(1):47~52.
[151]Formal S B , Baron L S , Kopecko D J , et al. Construction of a potential bivalent vaccine strain: introduction of Shigella sonnei from Ⅰantigen genes into the galE Salmonella typhimurium Ty21a typhoid vaccine strain . Infect Immune , 1981 , 34 :746~750.
[152]Hone D M, Harris A M, Chatfield S , et al. Construction of genetically defined double aro mutants of Salmonella typhimurium . Vaccine , 1991 , 9(11): 810~816.
[153]Attridge S R , Davies R , LaBrooy J T. Oral delivery of foreign antigens by attenuated Salmonella : consequences of prior exposure to the vector strain. Vaccine, 1997, 15(2) : 155~162.
[154] 江文正,金宁一。表达HIV-1结构蛋白靶细胞的制备及鉴定。中国生物制品学杂志,2003,16(2):70~71.
[155] Okamura H, Tsutsi H, Komatsu T, et al. Cloning of a new cytokine that induces IFN-gamma production by T cells. Nature,1995 , 378(6552):88~91.
[156] Hartikka J, Sawdey M, Jensen FC, et al. An improved plasmid DNA expression vector for direct injection into skeletal muscle. Human Gene Ther, 1996, 7(10):1205～1217
[157] Haddad D, Ramp rakash J , SedegahM , et al, Plasmid vaccine expressing granulocyte macrophage colony stimulating factor attracts infiltrates including immature dendritic cdeel into injected muscles. J Immuno l, 2000, 165: 3772~3781.
[158] Biet F, Locht C, Kremer L. Immunoregulatory functions of interleukin 18 and its role in defense against bacterial pathogens. J Mol Med. 2002 , 80(3):147~162.
[159] Scheerlinck JY.Genetic adjuvants for DNA vaccines. Vaccine. 2001, 19 (17-19): 2647~ 2656.